Clearside Biomedical is a late-stage clinical biopharmaceutical company developing pharmacological therapies to treat blinding diseases of the eye. Co.'s product candidates focus on diseases affecting the retina and the choroid. With its proprietary microinjector, drugs are injected into and spread through and via the suprachoroidal space, which is the space between the choroid and the outer protective layer of the eye known as the sclera. With the suprachoroidal injection, Co.'s product candidates are more directly administered to the retina and choroid. Co. holds the rights to develop and commercialize pharmacological agents for treatment of eye diseases via suprachoroidal injection.
Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
minutes; ETF data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.